Payment overview · 2025
General Payments
$699.29
16 reported records · 7 companies
Healthcare provider profile · identity verified
Thomas Patrick Bailey, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1952325094
Verified facts
What the public records show
CMS Open Payments records show Thomas Patrick Bailey, MD received $699.29 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $272.88 | 39.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $191.72 | 27.4% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.24 | 17.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41.79 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.06 | 4.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.71 | 3.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.89 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $699.29 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $239.15 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $148.19 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $121.24 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.53 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.53 | 3 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $41.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 173 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
173 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 511 | 130 |
| Lisinopril | Lisinopril | 444 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 436 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 66 |
| Metformin Hcl | Metformin Hcl | 285 | 69 |
| Furosemide | Furosemide | 242 | 39 |
| Omeprazole | Omeprazole | 237 | 50 |
| Gabapentin | Gabapentin | 231 | 30 |
| Allopurinol | Allopurinol | 186 | 34 |
| Ozempic | Semaglutide | 173 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 35 |
| Meloxicam | Meloxicam | 155 | 31 |
| Tramadol Hcl | Tramadol Hcl | 155 | 21 |
| Mounjaro | Tirzepatide | 147 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 37 |
| Potassium Chloride | Potassium Chloride | 137 | 22 |
| Eliquis | Apixaban | 125 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 35 |
| Losartan Potassium | Losartan Potassium | 107 | 28 |
| Sertraline Hcl | Sertraline Hcl | 99 | 12 |
| Farxiga | Dapagliflozin Propanediol | 96 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 17 |
| Trazodone Hcl | Trazodone Hcl | 94 | 14 |
| Prednisone | Prednisone | 88 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 14 |
| Xarelto | Rivaroxaban | 86 | 13 |
| Oxcarbazepine | Oxcarbazepine | 82 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 30 |
| Lorazepam | Lorazepam | 80 | 16 |
| Warfarin Sodium | Warfarin Sodium | 78 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 16 |
| Spironolactone | Spironolactone | 77 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 73 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 71 | 19 |
| Bupropion Xl | Bupropion Hcl | 70 | 16 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Jardiance | Empagliflozin | 65 | 15 |
| Lamotrigine | Lamotrigine | 65 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 64 | 21 |
| Cefuroxime | Cefuroxime Axetil | 63 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 18 |
| Donepezil Hcl | Donepezil Hcl | 57 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 20 |
| Finasteride | Finasteride | 55 | 13 |
| Simvastatin | Simvastatin | 55 | 18 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Atenolol | Atenolol | 50 | suppressed |
| Memantine Hcl | Memantine Hcl | 50 | 11 |
| Baclofen | Baclofen | 48 | suppressed |
| Fentanyl | Fentanyl | 48 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 13 |
| Carvedilol | Carvedilol | 46 | 12 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 11 |
| Klor-Con M20 | Potassium Chloride | 42 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 23 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | 11 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 18 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Fluconazole | Fluconazole | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Rybelsus | Semaglutide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $699.29 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Ozempic, Rybelsus, SYNCHROMEDII, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Veozah, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error